Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1969 Jul;36(3):582-93.
doi: 10.1111/j.1476-5381.1969.tb08013.x.

Steroid potentiation of responses to sympathomimetic amines in aortic strips

Steroid potentiation of responses to sympathomimetic amines in aortic strips

S Kalsner. Br J Pharmacol. 1969 Jul.

Abstract

1. Responses to catecholamines (adrenaline, noradrenaline, nordefrine) were enhanced by 17beta-oestradiol, progesterone and desoxycorticosterone in untreated and reserpine pretreated aortic strips. Responses to tyramine, believed mediated via endogenous catecholamines, were enhanced only in untreated strips.2. Responses to sympathomimetic amines lacking the catechol nucleus (phenylephrine, synephrine, methoxamine) were potentiated inconsistently by the steroids and reserpine pretreatment reduced markedly the frequency of potentiated responses.3. Known inhibitors of catechol-O-methyl transferase (tropolone, U-0521, pyrogallol) potentiated responses to catecholamines and abolished the enhancing effects of the steroids-when the steroids were given first, there was no further increase in response to catecholamines on adding inhibitors of catechol-O-methyl transferase.4. Experiments with the oil-immersion technique, to eliminate diffusion of drug from the tissue, indicated that 17beta-oestradiol, progesterone and desoxycorticosterone decreased the rate at which aortic strips inactivated adrenaline by O-methylation.5. It is concluded that 17beta-oestradiol, progesterone and desoxycorticosterone potentiate responses to catecholamines in aortic strips by inhibiting a major mechanism for their inactivation.

PubMed Disclaimer

References

    1. Br J Pharmacol. 1969 Mar;35(3):440-55 - PubMed
    1. Nature. 1963 May 11;198:547-8 - PubMed
    1. Biochim Biophys Acta. 1961 Nov 25;54:195-6 - PubMed
    1. J Pharmacol Exp Ther. 1969 Feb;165(2):152-65 - PubMed
    1. Can J Physiol Pharmacol. 1968 Sep;46(5):719-30 - PubMed

MeSH terms

LinkOut - more resources